A large, multicenter clinical trial involving several imaging modalities has found that plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.
A large, multicenter clinical trial involving several imaging modalities has found that plaque burden and plaques involving small lumen area are as likely as classically defined vulnerable plaques to trigger a myocardial infarction.
The trial, Providing Regional Observations to Study Predictors of Events in the Coronary Tree (PROSPECT), is the first prospective natural history study of atherosclerosis using multimodality imaging to characterize the coronary tree. The study findings were reported Sept. 24 at the Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in San Francisco. The Cardiovascular Research Foundation sponsored the five-day event.
"As a result of the PROSPECT trial, we are closer to being able to predict-and therefore prevent-sudden, unexpected adverse cardiac events," said principal investigator Dr. Gregg W. Stone, director of cardiovascular research and education at New York-Presbyterian Hospital/Columbia University Medical Center.
Stone and colleagues studied 700 patients with acute coronary syndromes using three-vessel multimodality intracoronary imaging. The modalities were x-ray angiography, intravascular ultrasound, and virtual histology involving a spectral analysis of radiofrequency data acquired with IVUS. They were used to quantify the clinical event rate from atherosclerotic progression and to identify those lesions that place patients at risk for unexpected adverse cardiovascular events (sudden death, cardiac arrest, heart attacks, and unstable or progressive angina).
Researchers discovered most untreated plaques that cause unexpected heart attacks are not mild lesions, as previously thought, but actually have a large plaque burden and a small lumen area. These are characteristics that were invisible to the coronary angiogram but easily identifiable on IVUS.
Only about half of new cardiac events were due to nonculprit lesions that exemplified the classic notion of vulnerable plaques (involving non–flow-limiting lesions with lipid cores encased in thin fibrosis caps) and associated inflammatory activity. Such abnormalities typically progress rapidly.
Another half was attributed to unrecognized and untreated severe disease with minimal change over time. Perhaps most important, for the first time it was demonstrated that characterization of the underlying plaque composition (with virtual histology) was able to significantly improve the ability to predict future adverse events beyond other, more standard, imaging techniques.
"These results mean that using a combination of imaging modalities, including IVUS, to identify lesions with a large plaque burden and/or small lumen area, and virtual histology to identify a large necrotic core without a visible cap (a thin-cap fibroatheroma) identifies the lesions that are at especially high risk of causing future adverse cardiovascular events," Stone said in a release.
New AI-Enabled Portable Ultrasound May Facilitate 50 Percent Reduction in Cardiac Imaging Scan Time
March 28th 2025Artificial intelligence (AI)-powered measurement capabilities provide key features with the Compact Ultrasound 5500CV device, which was unveiled at the American College of Cardiology (ACC) conference.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.